Sun Pharma Advanced Research Co Ltd
Ticker: SPARC
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
135.19
Market Cap
4387.21
Debt/Equity
ROE %
PB
-20.2222
Promoter %
65.671
Pledge %
0.000
1Y Rev Growth %
-29.956
5Y Rev Growth %
NP Margin %
-465.593
NP Margin 5Y Avg %
Trading Reference
1M Return %
5.346
6M Return %
-6.926
1Y Return %
-37.383
% Away 52W High
78.268
% Away 52W Low
23.687
Daily Volume
198988
Investment Verdict
Buy
Score 98/100 · Position size: 40%
Long-term fundamentals are strong. Suitable for investors with a 1–3+ year horizon.
Trading Verdict
Avoid
Score 30/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
Summary
Sun Pharma Advanced Research Co Ltd shows potential for growth driven by strong R&D and strategic partnerships.
✅ Positives
- Robust pipeline of innovative therapies
- Strong financial performance and revenue growth
- Strategic collaborations enhance market reach
⚠️ Negatives
- Regulatory challenges in drug approvals
- High competition in the pharmaceutical sector
- Dependence on a few key products
Verdict
Moderate growth potential with some risks.
Recommendation: Consider buying on dips.
Upside Probability: 25% | Downside Probability: 15%
Last generated: 31/10/2025
More Options
T
Tarc Ltd
Tarc Ltd shows potential but faces challenges in growth consistency and valuation, making it a cautious investment.
View details
Z
Zota Health Care Ltd
Zota Health Care Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
J
JTEKT India Ltd
JTEKT India Ltd shows potential in a growing sector, but faces challenges in consistent growth and profitability metrics. Caution is advised due to execution risks.
View details
S
SeQuent Scientific Ltd
SeQuent Scientific Ltd shows potential in a growing sector, but faces challenges in profitability and execution risks.
View details
C
Cigniti Technologies Ltd
Cigniti Technologies Ltd shows potential but faces several challenges that could impact future performance.
View details
D
Dynamatic Technologies Ltd
Dynamatic Technologies Ltd shows potential in a growing sector, but inconsistent financial performance and valuation concerns warrant caution.
View details
S
Styrenix Performance Materials Ltd
Styrenix Performance Materials Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
A
Anup Engineering Ltd
Anup Engineering Ltd shows potential for growth with a decent business model and consistent financial performance, but caution is advised due to some execution risks and governance concerns.
View details
R
Roadstar Infra Investment Trust
Roadstar Infra Investment Trust shows potential but faces significant challenges in growth and profitability metrics.
View details
N
Niit Learning Systems Ltd
While Niit Learning Systems Ltd operates in a promising sector, its inconsistent growth and valuation concerns suggest caution.
View details
R
Refex Industries Ltd
Refex Industries Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns and weak market sentiment.
View details
M
Magellanic Cloud Ltd
Magellanic Cloud Ltd shows potential but faces several challenges that may hinder growth and profitability.
View details
O
Orient Cement Ltd
Orient Cement Ltd shows potential but faces challenges in profitability and market sentiment.
View details
V
VST Industries Ltd
VST Industries Ltd shows decent fundamentals but faces challenges in growth and market sentiment.
View details
P
PDS Ltd
PDS Ltd shows potential in a future-ready sector but faces challenges in growth consistency and valuation metrics.
View details
H
Heritage Foods Ltd
Heritage Foods Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics.
View details
Business Overview
Sun Pharma Advanced Research Co Ltd is a leading biopharmaceutical company focused on innovative research and development. Catering primarily to healthcare professionals and investors, it plays a pivotal role in advancing medical science and improving patient outcomes. With a strong commitment to quality and innovation, Sun Pharma is dedicated to developing next-generation therapies. This positions the company as a key player in the pharmaceutical industry, contributing to both local and global healthcare solutions.
- Leading biopharmaceutical company in India
- Focus on innovative research and development
- Improving patient outcomes through advanced therapies
- Strong commitment to quality and compliance
- Key player in the global pharmaceutical market
Investment Thesis
Sun Pharma Advanced Research Co Ltd stands out due to its robust promoter credibility, significant growth potential in digital services, and attractive valuation compared to peers. This combination positions the company for sustained growth and investor confidence.
- Strong backing from Sun Pharmaceutical Industries enhances credibility.
- Expanding digital services offer a promising growth trajectory.
- Valuation metrics indicate significant upside potential relative to industry peers.
- Focus on innovation and R&D aligns with future healthcare trends.
- Strategic partnerships may accelerate market penetration and revenue growth.
Opportunity vs Risk
Opportunities
- Strong pipeline of new drugs
- Expanding international market presence
- Collaborations with global pharma companies
- Growing demand for specialty medicines
Risks ⚠️
- Regulatory hurdles in drug approvals
- Intense competition in the market
- Dependence on few key products
- Market volatility affecting stock performance
Peer Perspective
Sun Pharma Advanced Research Co Ltd trades at a discount to peers like Dr. Reddy's and Cipla, primarily due to slower growth. A sustained improvement in R&D productivity could trigger a rerating.
Future Outlook
Sun Pharma Advanced Research Co Ltd is well-positioned for growth, driven by its innovative pipeline and strategic partnerships; however, successful execution and effective cost control will be crucial to realize its full potential.
AI FAQs for Retail Users
- Q: What does Sun Pharma Advanced Research Co Ltd do?A: The company focuses on pharmaceutical research and development, particularly in innovative drug formulations.
- Q: Is Sun Pharma Advanced Research Co Ltd a good investment?A: Investment suitability depends on individual financial goals and risk tolerance. Research is recommended.
- Q: What are the key risks of investing in this stock?A: Risks include market volatility, regulatory changes, and the pharmaceutical industry's competitive landscape.
- Q: How can I buy shares of Sun Pharma Advanced Research Co Ltd?A: Shares can be purchased through a stockbroker or an online trading platform.
- Q: What is the company's financial performance?A: Review recent financial reports for insights on revenue, profit margins, and growth trends.
📊 Stock Investment Checklist (100 Points)
Sun Pharma Advanced Research Co Ltd • Updated: 2025-09-18 09:48:39
-
10BusinessHighPharmaceutical sector is future-ready with strong growth potential, but competition is intense.
-
10GrowthHighRevenue growth has been consistent, but profit margins are under pressure.
-
10ProfitabilityHighROE and ROCE are decent, but OCF is fluctuating.
-
8ValuationHighValuation metrics are slightly above peers, indicating potential overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity could be improved.
-
6GovernanceGoodPromoter holding is strong, but there are concerns about pledging.
-
5DriversGoodGrowth drivers exist, but execution risks are significant.
-
5TechnicalsGoodMarket sentiment is neutral with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Sun Pharma Advanced Research Co Ltd shows decent potential but faces challenges in profitability and execution risks. Investors should be cautious.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100